세계 구강 건조증(드라이 마우스) 치료 시장 : 제품 유형별, 최종 사용자별, 지역별 - 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Persistence Market Research has recently published an in-depth analysis of the global Pyrogen Testing Market, offering a comprehensive overview of key market dynamics, growth drivers, challenges, and emerging trends. This report provides valuable insights into the Pyrogen Testing Market, presenting exclusive data and statistics that forecast the market's growth trajectory from 2024 to 2032.

The global market for xerostomia (dry mouth) treatment, valued at US$ 113.7 million in 2024, is projected to expand at a compound annual growth rate (CAGR) of 6.1%, reaching US$ 1.81 billion by 2032.

Key Insights:

• Xerostomia Treatment Market Size (2024) - US$ 113.7 Mn
• Predicted Market Value (2032) - US$ 1.81 Bn
• Global Market Growth Rate (2024-2032) - 6.1% CAGR

Xerostomia (Dry Mouth) Treatment Market - Report Scope:

Xerostomia, commonly known as dry mouth, is a condition characterized by a lack of saliva production, leading to discomfort and potential oral health issues. The report explores various treatment modalities and advancements in addressing xerostomia, catering to a diverse patient population across different demographics.

Market Growth Drivers:

The Xerostomia Treatment Market is driven by several factors, including the aging population, increasing prevalence of xerostomia associated with various medical conditions and medications, and growing awareness about oral health. Moreover, advancements in treatment options, such as saliva substitutes, prescription medications, and innovative therapies, contribute to market expansion.

Market Restraints:

Despite growth prospects, challenges exist within the Xerostomia Treatment Market. These include limited treatment efficacy for certain patient populations, adverse effects associated with some treatment modalities, and accessibility issues in certain regions. Additionally, the underdiagnosis and undertreatment of xerostomia pose barriers to market penetration.

Market Opportunities:

The Xerostomia Treatment Market presents significant opportunities for innovation and research. Continued efforts in developing novel treatment modalities with improved efficacy and safety profiles, as well as targeted interventions for specific patient groups, can enhance market growth. Moreover, expanding awareness campaigns and educational initiatives can aid in early detection and management of xerostomia, fostering market expansion.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Xerostomia Treatment Market?
• Which demographic groups are most affected by xerostomia, and what are their treatment preferences?
• How are technological advancements reshaping the competitive landscape of the Xerostomia Treatment Market?
• Who are the leading players in the global Xerostomia Treatment Market?
• What emerging trends and future prospects are anticipated in the global Xerostomia Treatment Market?

Competitive Intelligence and Business Strategy:

Leading suppliers of xerostomia treatment products are enhancing their market presence through collaboration and joint ventures. Key players in the industry are actively seeking approvals from regulatory authorities such as the FDA or DCGA to launch new product variants, aiming to expand their market reach.

Key Companies Profiled:

• GlaxoSmithKline Plc
• Daiichi Pharmaceutical Co., Ltd.
• Bausch Health Companies Inc. (OraPharma)
• ADVANZ PHARMA Corp. Limited
• CCMed Ltd.
• Elevate Oral Care, LLC
• Orahealth Corporation
• Forward Science
• Parnell Pharmaceuticals, Inc
• Cyclacel Pharmaceuticals, Inc.
• Midatech Pharma Plc.
• Perrigo Company Plc.
• Entod International
• Laboratories Kin, SA
• ICPA HEALTH PRODUCTS Ltd
• Biocosmetic Laboratories
• The 3M Company
• Mission Pharmacal Company
• Chattem, Inc. (Sanofi)
• Cipla Ltd.
• Fresenius Kabi
• Colgate-Palmolive Company
• EUSA Pharma

Xerostomia (Dry Mouth) Treatment Market Segmentation:

Xerostomia Treatment Market by Product:

• Oral Sprays
• Oral Solutions
• Oral Liquids
• Gels
• Powders

Xerostomia Treatment Market by Age Group:

• Paediatrics
• Adults

Early Adults (18-34 Years)

Early Middle Age (35 - 44 Years)

Late Middle Age (45 - 64 Years)

Late Adulthood (Above 65+Years)

Xerostomia Treatment Market by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Mail Order Pharmacies
• Hypermarkets and Supermarkets

Xerostomia Treatment Market by Region:

• North America Xerostomia Treatment Market
• Latin America Xerostomia Treatment Market
• Europe Xerostomia Treatment Market
• South Asia Xerostomia Treatment Market
• East Asia Xerostomia Treatment Market
• Oceania Xerostomia Treatment Market
• Middle East & Africa Xerostomia Treatment Market

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusion and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Market Background

• 4.1. Macro-Economic Factors
  • 4.1.1. Global GDP Outlook
  • 4.1.2. Increasing Spending on Healthcare Per Capita
  • 4.1.3. High Spending on Oral Care Products
  • 4.1.4. Supply Chain Model Issues
• 4.2. Forecast Factors - Relevance & Impact
  • 4.2.1. GDP Growth
  • 4.2.2. Increasing Investments in R&D Activities
  • 4.2.3. High prevalence of xerostomia
  • 4.2.4. Treatment Seeking Rate (%)
  • 4.2.5. Disposable income
  • 4.2.6. Average duration of treatment
  • 4.2.7. Dosage Pattern (%)
  • 4.2.8. Overall Treatment cost
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunity Analysis

5. COVID19 Crisis Analysis

• 5.1. Current COVID19 Probable Future Impact
• 5.2. COVID19 and Impact Analysis
  • 5.2.1. Revenue by Product
  • 5.2.2. Revenue by Age Group
  • 5.2.3. Revenue by Distribution Channel
  • 5.2.4. Revenue by Country

6. Value Added Insights

• 6.1. Disease Epidemiology
• 6.2. Regulatory Scenario
• 6.3. PESTLE Analysis
• 6.4. Porters Analysis
• 6.5. Key Promotional Strategies by Manufacturers

7. Global Xerostomia (Dry Mouth) Treatment Market Value (US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (In Value or Size in US$ Mn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Product

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (In Value or Size in US$ Mn) & Volume Trend, By Product, 2019-2023
• 8.3. Current and Future Market Size (In Value or Size in US$ Mn) & Volume Trend Analysis and Forecast, By Product, 2024-2032
  • 8.3.1. Product
    • 8.3.1.1. Oral Spray
    • 8.3.1.2. Oral Solution
    • 8.3.1.3. Oral Liquid
    • 8.3.1.4. Gel
    • 8.3.1.5. Powder
• 8.4. Market Attractiveness Analysis, By Product

9. Global Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Age Group

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (In Value or Size in US$ Mn) Trend, By Age Group, 2019-2023
• 9.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis and Forecast, By Age Group, 2024-2032
  • 9.3.1. Pediatric
  • 9.3.2. Adult
    • 9.3.2.1. Early Adults (18-34)
    • 9.3.2.2. Early Middle Age (35 - 44)
    • 9.3.2.3. Late Middle Age (45 - 64)
    • 9.3.2.4. Late Adulthood (Above 65+)
• 9.4. Market Attractiveness Analysis, By Age Group

10. Global Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (In Value or Size in US$ Mn) Trend, By End User, 2019-2023
• 10.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis and Forecast, By Distribution Channel, 2024-2032
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Drug Stores
  • 10.3.4. Mail Order Pharmacies
  • 10.3.5. Hypermarkets and Supermarkets
• 10.4. Market Attractiveness Analysis, By Distribution Channel

11. Global Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Region

• 11.1. Introduction
• 11.2. Historical Market Size (In Value or Size in US$ Mn) Analysis, By Region, 2019-2023
• 11.3. Current Market Size (In Value or Size in US$ Mn) Analysis and Forecast, By Region, 2024-2032
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. South Asia
  • 11.3.5. East Asia
  • 11.3.6. Oceania
  • 11.3.7. Middle East and Africa (MIDDLE EAST & AFRICA)
• 11.4. Market Attractiveness Analysis, By Region

12. North America Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 12.1. Introduction
• 12.2. Historical Market Size (In Value or Size in US$ Mn Trend Analysis, By Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast, By Market Taxonomy, 2024-2032
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Product
  • 12.3.3. By Age Group
  • 12.3.4. By Distribution Channel
• 12.4. Market Attractiveness Analysis
• 12.5. Key Market Participants - Intensity Mapping
• 12.6. Drivers and Restraints - Impact Analysis

13. Latin America Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast, By Market Taxonomy, 2024-2032
  • 13.3.1. By Country
    • 13.3.1.1. Brazil
    • 13.3.1.2. Mexico
    • 13.3.1.3. Argentina
    • 13.3.1.4. Rest of Latin America
  • 13.3.2. By Product
  • 13.3.3. By Age Group
  • 13.3.4. By Distribution Channel
• 13.4. Market Attractiveness Analysis
• 13.5. Key Market Participants - Intensity Mapping
• 13.6. Drivers and Restraints - Impact Analysis

14. Europe Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast, By Market Taxonomy, 2024-2032
  • 14.3.1. By Country
    • 14.3.1.1. Germany
    • 14.3.1.2. Italy
    • 14.3.1.3. France
    • 14.3.1.4. U.K.
    • 14.3.1.5. Spain
    • 14.3.1.6. BENELUX
    • 14.3.1.7. Russia
    • 14.3.1.8. Rest of Europe
  • 14.3.2. By Product
  • 14.3.3. By Age Group
  • 14.3.4. By Distribution Channel
• 14.4. Market Attractiveness Analysis
• 14.5. Key Market Participants - Intensity Mapping
• 14.6. Drivers and Restraints - Impact Analysis

15. South Asia and Pacific Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast, By Market Taxonomy, 2024-2032
  • 15.3.1. By Country
    • 15.3.1.1. India
    • 15.3.1.2. Thailand
    • 15.3.1.3. Indonesia
    • 15.3.1.4. Malaysia
    • 15.3.1.5. Rest of South Asia
  • 15.3.2. By Product
  • 15.3.3. By Age Group
  • 15.3.4. By Distribution Channel
• 15.4. Market Attractiveness Analysis
• 15.5. Key Market Participants - Intensity Mapping
• 15.6. Drivers and Restraints - Impact Analysis

16. East Asia Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast, By Market Taxonomy, 2024-2032
  • 16.3.1. By Country
    • 16.3.1.1. China
    • 16.3.1.2. Japan
    • 16.3.1.3. South Korea
  • 16.3.2. By Product
  • 16.3.3. By Age Group
  • 16.3.4. By Distribution Channel
• 16.4. Market Attractiveness Analysis
• 16.5. Key Market Participants - Intensity Mapping
• 16.6. Drivers and Restraints - Impact Analysis

17. Oceania Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast, By Market Taxonomy, 2024-2032
  • 17.3.1. By Country
    • 17.3.1.1. Australia
    • 17.3.1.2. New Zealand
  • 17.3.2. By Product
  • 17.3.3. By Age Group
  • 17.3.4. By Distribution Channel
• 17.4. Market Attractiveness Analysis
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Xerostomia (Dry Mouth) Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 18.1. Introduction
• 18.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast, By Market Taxonomy, 2024-2032
  • 18.3.1. By Country
    • 18.3.1.1. GCC Countries
    • 18.3.1.2. Turkey
    • 18.3.1.3. South Africa
    • 18.3.1.4. Rest of Middle East and Africa
  • 18.3.2. By Product
  • 18.3.3. By Age Group
  • 18.3.4. By Distribution Channel
• 18.4. Market Attractiveness Analysis
• 18.5. Key Market Participants - Intensity Mapping
• 18.6. Drivers and Restraints - Impact Analysis

19. Country Level Xerostomia (Dry Mouth) Treatment Market Analysis 2022 & 2032

• 19.1. Introduction
  • 19.1.1. Market Value (US$ Mn) Proportion Analysis, By Country
  • 19.1.2. Global Vs. Country Growth Comparison
• 19.2. U.S. Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.2.1. By Product
  • 19.2.2. By Age Group
  • 19.2.3. By Distribution Channel
• 19.3. Canada Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.3.1. By Product
  • 19.3.2. By Age Group
  • 19.3.3. By Distribution Channel
• 19.4. Brazil Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.4.1. By Product
  • 19.4.2. By Age Group
  • 19.4.3. By Distribution Channel
• 19.5. Mexico Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.5.1. By Product
  • 19.5.2. By Age Group
  • 19.5.3. By Distribution Channel
• 19.6. Argentina Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.6.1. By Product
  • 19.6.2. By Age Group
  • 19.6.3. By Distribution Channel
• 19.7. Germany Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.7.1. By Product
  • 19.7.2. By Age Group
  • 19.7.3. By Distribution Channel
• 19.8. Italy Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.8.1. By Product
  • 19.8.2. By Age Group
  • 19.8.3. By Distribution Channel
• 19.9. France Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.9.1. By Product
  • 19.9.2. By Age Group
  • 19.9.3. By Distribution Channel
• 19.10. U.K. Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.10.1. By Product
  • 19.10.2. By Age Group
  • 19.10.3. By Distribution Channel
• 19.11. Spain Mexico Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.11.1. By Product
  • 19.11.2. By Age Group
  • 19.11.3. By Distribution Channel
• 19.12. BENELUX Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.12.1. By Product
  • 19.12.2. By Age Group
  • 19.12.3. By Distribution Channel
• 19.13. Russia Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.13.1. By Product
  • 19.13.2. By Age Group
  • 19.13.3. By Distribution Channel
• 19.14. India Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.14.1. By Product
  • 19.14.2. By Age Group
  • 19.14.3. By Distribution Channel
• 19.15. Thailand Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.15.1. By Product
  • 19.15.2. By Age Group
  • 19.15.3. By Distribution Channel
• 19.16. Indonesia Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.16.1. By Product
  • 19.16.2. By Age Group
  • 19.16.3. By Distribution Channel
• 19.17. Malaysia Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.17.1. By Product
  • 19.17.2. By Age Group
  • 19.17.3. By Distribution Channel
• 19.18. China Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.18.1. By Product
  • 19.18.2. By Age Group
  • 19.18.3. By Distribution Channel
• 19.19. Japan Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.19.1. By Product
  • 19.19.2. By Age Group
  • 19.19.3. By Distribution Channel
• 19.20. South Korea Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.20.1. By Product
  • 19.20.2. By Age Group
  • 19.20.3. By Distribution Channel
• 19.21. Australia Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.21.1. By Product
  • 19.21.2. By Age Group
  • 19.21.3. By Distribution Channel
• 19.22. New Zealand Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.22.1. By Product
  • 19.22.2. By Age Group
  • 19.22.3. By Distribution Channel
• 19.23. GCC Countries Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.23.1. By Product
  • 19.23.2. By Age Group
  • 19.23.3. By Distribution Channel
• 19.24. Turkey Xerostomia (Dry Mouth) Treatment Market Value (US$) Analysis
  • 19.24.1. By Product
  • 19.24.2. By Age Group
  • 19.24.3. By Distribution Channel
• 19.25. South Africa Xerostomia (Dry Mouth) Treatment Market Value (US$) and Analysis
  • 19.25.1. By Product
  • 19.25.2. By Age Group
  • 19.25.3. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis, By Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis
  • 20.3.1. Regional footprint of Players
  • 20.3.2. Product foot print by Players
  • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. GlaxoSmithKline Plc
    • 21.3.1.1. Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Key Financials
    • 21.3.1.4. Sales Footprint
    • 21.3.1.5. Strategy Overview
      • 21.3.1.5.1. Marketing Strategy
      • 21.3.1.5.2. Product Strategy
      • 21.3.1.5.3. Channel Strategy
  • 21.3.2. Daiichi Pharmaceutical Co., Ltd.
    • 21.3.2.1. Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Key Financials
    • 21.3.2.4. Sales Footprint
    • 21.3.2.5. Strategy Overview
      • 21.3.2.5.1. Marketing Strategy
      • 21.3.2.5.2. Product Strategy
      • 21.3.2.5.3. Channel Strategy
  • 21.3.3. Bausch Health Companies Inc. (OraPharma)
    • 21.3.3.1. Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Key Financials
    • 21.3.3.4. Sales Footprint
    • 21.3.3.5. Strategy Overview
      • 21.3.3.5.1. Marketing Strategy
      • 21.3.3.5.2. Product Strategy
      • 21.3.3.5.3. Channel Strategy
  • 21.3.4. ADVANZ PHARMA Corp. Limited
    • 21.3.4.1. Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Key Financials
    • 21.3.4.4. Sales Footprint
    • 21.3.4.5. Strategy Overview
      • 21.3.4.5.1. Marketing Strategy
      • 21.3.4.5.2. Product Strategy
      • 21.3.4.5.3. Channel Strategy
  • 21.3.5. CCMed Ltd.
    • 21.3.5.1. Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Key Financials
    • 21.3.5.4. Sales Footprint
    • 21.3.5.5. Strategy Overview
      • 21.3.5.5.1. Marketing Strategy
      • 21.3.5.5.2. Product Strategy
      • 21.3.5.5.3. Channel Strategy
  • 21.3.6. Elevate Oral Care, LLC
    • 21.3.6.1. Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Key Financials
    • 21.3.6.4. Sales Footprint
    • 21.3.6.5. Strategy Overview
      • 21.3.6.5.1. Marketing Strategy
      • 21.3.6.5.2. Product Strategy
      • 21.3.6.5.3. Channel Strategy
  • 21.3.7. Orahealth Corporation
    • 21.3.7.1. Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Key Financials
    • 21.3.7.4. Sales Footprint
    • 21.3.7.5. Strategy Overview
      • 21.3.7.5.1. Marketing Strategy
      • 21.3.7.5.2. Product Strategy
      • 21.3.7.5.3. Channel Strategy
  • 21.3.8. Forward Science
    • 21.3.8.1. Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Key Financials
    • 21.3.8.4. Sales Footprint
    • 21.3.8.5. Strategy Overview
      • 21.3.8.5.1. Marketing Strategy
      • 21.3.8.5.2. Product Strategy
      • 21.3.8.5.3. Channel Strategy
  • 21.3.9. Parnell Pharmaceuticals, Inc
    • 21.3.9.1. Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Key Financials
    • 21.3.9.4. Sales Footprint
    • 21.3.9.5. Strategy Overview
      • 21.3.9.5.1. Marketing Strategy
      • 21.3.9.5.2. Product Strategy
      • 21.3.9.5.3. Channel Strategy
  • 21.3.10. Cyclacel Pharmaceuticals, Inc.
    • 21.3.10.1. Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Key Financials
    • 21.3.10.4. Sales Footprint
    • 21.3.10.5. Strategy Overview
      • 21.3.10.5.1. Marketing Strategy
      • 21.3.10.5.2. Product Strategy
      • 21.3.10.5.3. Channel Strategy
  • 21.3.11. Midatech Pharma Plc.
    • 21.3.11.1. Overview
    • 21.3.11.2. Product Portfolio
    • 21.3.11.3. Key Financials
    • 21.3.11.4. Sales Footprint
    • 21.3.11.5. Strategy Overview
      • 21.3.11.5.1. Marketing Strategy
      • 21.3.11.5.2. Product Strategy
      • 21.3.11.5.3. Channel Strategy
  • 21.3.12. Perrigo Company Plc.
    • 21.3.12.1. Overview
    • 21.3.12.2. Product Portfolio
    • 21.3.12.3. Key Financials
    • 21.3.12.4. Sales Footprint
    • 21.3.12.5. Strategy Overview
      • 21.3.12.5.1. Marketing Strategy
      • 21.3.12.5.2. Product Strategy
      • 21.3.12.5.3. Channel Strategy
  • 21.3.13. Entod International
    • 21.3.13.1. Overview
    • 21.3.13.2. Product Portfolio
    • 21.3.13.3. Key Financials
    • 21.3.13.4. Sales Footprint
    • 21.3.13.5. Strategy Overview
      • 21.3.13.5.1. Marketing Strategy
      • 21.3.13.5.2. Product Strategy
      • 21.3.13.5.3. Channel Strategy
  • 21.3.14. Laboratories Kin, SA
    • 21.3.14.1. Overview
    • 21.3.14.2. Product Portfolio
    • 21.3.14.3. Key Financials
    • 21.3.14.4. Sales Footprint
    • 21.3.14.5. Strategy Overview
      • 21.3.14.5.1. Marketing Strategy
      • 21.3.14.5.2. Product Strategy
      • 21.3.14.5.3. Channel Strategy
  • 21.3.15. ICPA HEALTH PRODUCTS Ltd
    • 21.3.15.1. Overview
    • 21.3.15.2. Product Portfolio
    • 21.3.15.3. Key Financials
    • 21.3.15.4. Sales Footprint
    • 21.3.15.5. Strategy Overview
      • 21.3.15.5.1. Marketing Strategy
      • 21.3.15.5.2. Product Strategy
      • 21.3.15.5.3. Channel Strategy
  • 21.3.16. Biocosmetic Laboratories
    • 21.3.16.1. Overview
    • 21.3.16.2. Product Portfolio
    • 21.3.16.3. Key Financials
    • 21.3.16.4. Sales Footprint
    • 21.3.16.5. Strategy Overview
      • 21.3.16.5.1. Marketing Strategy
      • 21.3.16.5.2. Product Strategy
      • 21.3.16.5.3. Channel Strategy
  • 21.3.17. The 3M Company
    • 21.3.17.1. Overview
    • 21.3.17.2. Product Portfolio
    • 21.3.17.3. Key Financials
    • 21.3.17.4. Sales Footprint
    • 21.3.17.5. Strategy Overview
      • 21.3.17.5.1. Marketing Strategy
      • 21.3.17.5.2. Product Strategy
      • 21.3.17.5.3. Channel Strategy
  • 21.3.18. Mission Pharmacal Company
    • 21.3.18.1. Overview
    • 21.3.18.2. Product Portfolio
    • 21.3.18.3. Key Financials
    • 21.3.18.4. Sales Footprint
    • 21.3.18.5. Strategy Overview
      • 21.3.18.5.1. Marketing Strategy
      • 21.3.18.5.2. Product Strategy
      • 21.3.18.5.3. Channel Strategy
  • 21.3.19. Chattem, Inc. (Sanofi)
    • 21.3.19.1. Overview
    • 21.3.19.2. Product Portfolio
    • 21.3.19.3. Key Financials
    • 21.3.19.4. Sales Footprint
    • 21.3.19.5. Strategy Overview
      • 21.3.19.5.1. Marketing Strategy
      • 21.3.19.5.2. Product Strategy
      • 21.3.19.5.3. Channel Strategy
  • 21.3.20. Cipla Ltd.
    • 21.3.20.1. Overview
    • 21.3.20.2. Product Portfolio
    • 21.3.20.3. Key Financials
    • 21.3.20.4. Sales Footprint
    • 21.3.20.5. Strategy Overview
      • 21.3.20.5.1. Marketing Strategy
      • 21.3.20.5.2. Product Strategy
      • 21.3.20.5.3. Channel Strategy
  • 21.3.21. Fresenius Kabi
    • 21.3.21.1. Overview
    • 21.3.21.2. Product Portfolio
    • 21.3.21.3. Key Financials
    • 21.3.21.4. Sales Footprint
    • 21.3.21.5. Strategy Overview
      • 21.3.21.5.1. Marketing Strategy
      • 21.3.21.5.2. Product Strategy
      • 21.3.21.5.3. Channel Strategy
  • 21.3.22. Colgate-Palmolive Company
    • 21.3.22.1. Overview
    • 21.3.22.2. Product Portfolio
    • 21.3.22.3. Key Financials
    • 21.3.22.4. Sales Footprint
    • 21.3.22.5. Strategy Overview
      • 21.3.22.5.1. Marketing Strategy
      • 21.3.22.5.2. Product Strategy
      • 21.3.22.5.3. Channel Strategy
  • 21.3.23. EUSA Pharma
    • 21.3.23.1. Overview
    • 21.3.23.2. Product Portfolio
    • 21.3.23.3. Key Financials
    • 21.3.23.4. Sales Footprint
    • 21.3.23.5. Strategy Overview
      • 21.3.23.5.1. Marketing Strategy
      • 21.3.23.5.2. Product Strategy
      • 21.3.23.5.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology